Increased Platelet Glycoprotein V Levels in Patients with Coronary and Peripheral Atherosclerosis

A. D. Blann; F. Lanza; P. Galajda; D. Gurney; S. Moog; J. P. Cazenave; G. Y. H. Lip

doi:10.1055/s-0037-1616131

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 86(03): 777-783
DOI: 10.1055/s-0037-1616131

Review Articles

Schattauer GmbH

Increased Platelet Glycoprotein V Levels in Patients with Coronary and Peripheral Atherosclerosis

The Influence of Aspirin and Cigarette Smoking

Authors

A. D. Blann

¹Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
F. Lanza

²INSERM U.311, Etablissement Francais du Sang, Strasbourg, France
P. Galajda

¹Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
D. Gurney

¹Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
S. Moog

²INSERM U.311, Etablissement Francais du Sang, Strasbourg, France
J. P. Cazenave

²INSERM U.311, Etablissement Francais du Sang, Strasbourg, France
G. Y. H. Lip

¹Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK

Abstract

Summary

As platelet hyperactivity is important in atherosclerosis and smoking, we hypothesized higher levels of soluble platelet membrane glycoprotein V (gpV) in 95 patients with peripheral artery disease (PAD) and 92 with coronary artery disease (CAD) compared to 99 healthy controls, and examined the effects of aspirin and of smoking two cigarettes on soluble gpV and platelet function. Soluble gpV (ELISA) was significantly raised in, but not between, both PAD and CAD patients, compared to controls (p <0.05). In multivariate analysis, systolic blood pressure, smoking and atherosclerosis (all p <0.01) were significant influences on soluble gpV in the whole study cohort. There was a weak correlation between soluble gpV and another platelet marker, soluble P selectin (p = 0.048). Acute smoking in 14 subjects increased platelet aggregability and beta-thromboglobulin, but not soluble gpV: there were no changes in 11 non-smokers. Five days consumption of aspirin (325 mg daily) by 14 subjects did not influence levels of soluble gpV. Our data indicate that soluble gpV may be a useful new marker of platelet activation in atherosclerosis, but may be influenced by smoking status and blood pressure.

Keywords

Platelets - smoking - atherosclerosis

Full Text

References

References
1 McGill DA, Ardlie NG. Abnormal platelet reactivity in men with premature coronary artery disease. Coronary Artery Dis 1994; 5: 899-900.
2 Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiber L. Increased platelet and coagulatory activity indicate ongoing thrombo-genesis in peripheral arterial disease. Thromb Res 1996; 82: 523-43.
3 Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation 1992; 86 [suppl III] III-95-III-99.
4 Dormany JA. Rationale for antiplatelet therapy in patients with atherothrombotic disease. Vascular Med 1998; 3: 253-5.
5 D’Souza D, Wu KK, Hellums JD, Phillips MD. Platelet activation and arterial thrombosis. Lancet 1994; 344: 991-5.
6 Martin JF, Bath PMW, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-11.
7 Cahill MR, Newland AC. Platelet activation in coronary artery disease. Br J Biomed Sci 1993; 50: 221-34.
8 Files JC, Malpass TW, Yee EK, Ritchie JL, Harker LA. Studies of human platelet alpha granule release in vivo. Blood 1981; 58: 607-18.
9 Matzdorff AC, Kemkes-Matthes B, Voss R, Pralle H. Comparison of beta thromboglobulin, flow cytometry and platelet aggregometry to study platelet activation. Haemostasis 1996; 26: 98-106.
10 Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P selectin is increased in thrombotic consumptive disorders. Blood 1994; 83: 1535-41.
11 Blann AD, Steele C, McCollum CN. The influence of smoking on soluble adhesion molecules and endothelial cell markers. Thromb Res 1997; 85: 433-8.
12 Jilma B, Fasching P, Ruthner C, Rumplmayr A, Ruzicka S, Kapiotis S, Wagner OF, Eichler HG. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 1996; 76: 328-32.
13 Nowak J, Murray JJ, Oates JA, Fitzgerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76: 6-14.
14 Davis JW, Shelton L, Eigenberg DA, Hignite CE, Watanabe IS. Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets. Clin Pharmacol Ther 1985; 37: 529-33.
15 Blache D, Bouthillier D, Davignon J. Acute influence of smoking on platelet behaviour, endothelium and plasma lipids and normalisation by aspirin. Atherosclerosis 1992; 93: 179-88.
16 Wennmalm A, Benthin G, Granstrom EF, Persson L, Petersson AS, Winell S. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation 1991; 83: 1698-704.
17 Lanza F, Morales M, de La Salle C, Cazenave JP, Clementson KJ, Shimomura T, Phillips DR. Cloning and characterisation of the gene encoding the human platelet glycoprotein V. A member of the leucine-rich glycoprotein family cleaved during thrombin-induced platelet activation. J Biol Chem 1993; 268: 20801-7.
18 Hickey MJ, Hagen FS, Yagi M, Roth GJ. Human platelet glycoprotein V: characterisation of the polypeptide and the related Ib-V-IX receptor system of adhesive, leucine rich glycoproteins. Proc Natl Acad Sci USA 1993; 90: 8327-31.
19 Azorsa DO, Moog S, Ravanat C, Schuhler S, Follea G, Cazenave JP, Lanza F. Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA – its use to follow platelet storage in transfusion. Thromb Haemost 1999; 81: 131-8.
20 Ravanat C, Freund M, Mangin P, Azorsa DO, Schwartz C, Moog S, Schuhler, Dambach J Cazenave JP, Lanza F. GPV is a marker of in vivo platelet activation – study in a rat thrombosis model. Thromb Haemost 2000; 83: 327-33.
21 Belch JJF, McArdle BM, Burns P, Lowe GDO, Forbes CD. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorheology in habitual smokers. Thromb Haemost 1984; 51: 6-8.
22 Blann AD, Kirkpatrick U, Devine C, Naser S, McCollum CN. The influence of acute smoking on leukocytes, platelets and the endothelium. Atherosclerosis 1998; 141: 1331-9.
23 Schmidt KG, Rasmussen JW, Bonnevie-Nielsen V. Acute platelet activation induced by smoking cigarettes: In vivo and in vitro studies in humans. In ‘Tobacco smoking and atherosclerosis’. Diana JN. (Ed.) Plenus Press; New York: 1990
24 Altman DG. ‘Practical statistics for medical research’. Chapman & Hall; London: 1991
25 Minitab Inc, 3081 Enterprise Drive, State College, PA 16801-3008 USA.
26 Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of smoking. Am Heart J 1994; 128: 7-11.
27 Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-7.
28 Fitzgerald DJ, Roy L, Catella F, Fitzgerald G. Platelet activation in unstable coronary disease. New Engl J Med 1986; 315: 983-9.
29 Duncan A, Depratti VJ, George RR. Elevated beta thromboglobulin levels associated with smoking and oral contraceptive agents in healthy women. Thromb Res 1981; 21: 425-30.
30 Bartecchi CE, MacKenzie TD, Schrier RW. The human cost of tobacco use. New Engl J Med 1994; 330: 907-12.
31 Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. Br Med J 1994; 309: 901-11.
32 Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg 1991; 5: 291-304.
33 Blann AD, Lip GYH. Is soluble P-selectin a new marker of platelet activation?. Atherosclerosis 1997; 128: 135-8.
34 Michelson AD, Benoit SE, Furman MI, Barnard MR, Nurden P, Nurden AT. The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible-mediated redistribution to the surface-connected canalicular system. Blood 1996; 87: 1396-408.
35 Criqui MH, Wallace RB, Heiss G, Mishkel M, Schonfeld G, Jones GT. Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62: IV70-IV76.
36 Lip GYH, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecules P-selectin, and endothelial dysfunction in essential hypertension: Implications for atherogenesis? A preliminary report. J Hypertens 1995; 13: 1674-8.
37 James IM, Dickensen EJ, Burgoyne W, Jeremy JY, Barradas MA, Mikhailidis DP, Dandona P. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Human Hypertens 1988; 2: 21-5.
38 Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Human Hypertens 1994; 8: 273-8.
39 Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface bound P-selectin in detecting platelet activity in patients with congestive heart failure. Am J Cardiol 1999; 83: 1345-9.
40 Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Euchler HG, Vondrovec B, Amiral J, Richter V, Wagner OF. Regulation of adhesion molecules during human endotoxaemia. No acute effects of aspirin. Amer J Respir Crit Care Med 1999; 159: 857-63.
41 Kaplan KL, Owen J. Plasma levels of beta thromboglobulin and platelet factor four as indices of platelet activation in vivo. Blood 1981; 57: 199-202.
42 Dawes J, Smith RC, Pepper DC. The release, distribution and clearance of human beta thromboglobulin and Platelet Factor 4. Thromb Res 1978; 12: 569-82.